SUMMARY
INTRODUCTION
Reactive oxygen species (ROS) are continuously generated by cells to regulate cellular responses such as proliferation, differentiation, and apoptosis (Finkel, 2003) . ROS modulate signaling molecules through reversible posttranslational reductive and oxidative modification of protein structures. Specific cysteine thiol groups (R-SH) are oxidized to sulfenic acid (R-SOH), followed by rapid interaction with other protein thiol groups to form disulfide bonds. Disulfide bond formation within redoxsensitive proteins regulates subcellular localization, proteinprotein interactions, and protein structure, thereby regulating their functional activity. Sulfenic acid is vulnerable to further, largely irreversible, oxidation, forming either sulfinic acid (R-SO 2 À2 ) or sulfonic acid (R-SO 3 À2 ) (Berndt et al., 2007) . Excess ROS generation, termed oxidative stress, is involved in the pathogenesis of various diseases, such as cardiovascular disease, neurodegenerative disease, and inflammation. However, under physiological conditions, excess ROS are usually removed by scavenging systems such as thioredoxin (Trx) and glutathione (GSH) (Berndt et al., 2007) . Mammalian Trx1 contains a common disulfide active motif, Cys-Gly-Pro-Cys. Trx1 catalyzes disulfide reduction through a thiol-disulfide exchange reaction involving Cys32 and Cys35 in its active site, leaving the target protein reduced and Trx1 oxidized (Kallis and Holmgren, 1980) . Oxidized Trx1 is reduced and regenerated by Trx1 reductase using electrons from NADPH (Mustacich and Powis, 2000) . Trx1 acts both as a major disulfide reductase, thereby maintaining the cellular thiol redox homeostasis, and as a modulator of transcription factors and kinases, regulating their activities in a redox-dependent manner .
ROS, produced by mitochondrial leakage and other enzymatic sources, are associated with cardiovascular diseases. Trx1 activity is essential for reducing oxidative stress, inhibiting cardiac hypertrophy, and attenuating cardiac cell death (Ago et al., 2008) . Trx1 not only maintains the intracellular redox balance by regenerating active peroxiredoxin but also acts as a signaling molecule to transduce signals to other effectors. For example, Trx1 inhibits apoptosis by negatively regulating apoptosis signal-regulating kinase (ASK1) and Ras in cardiomyocytes (Kuster et al., 2005; Saitoh et al., 1998) and prevents cardiac hypertrophy by reducing Class II histone deacetylases (HDACs) and inhibiting their nuclear export (Ago et al., 2008) . Identification of the molecular targets of Trx1 is therefore an important step in understanding the key signaling events mediating cardiovascular pathogenesis.
Using unbiased proteomic approaches, we showed that Trx1 reduces proteins involved in cardiac energy dynamics (Fu et al., 2009) . Trx1 also plays an important protective role during ischemia and reperfusion, which cause energy stress and eventual cell death in the heart (Tao et al., 2004) . We predict that Trx1 protects the heart by reducing critical molecules involved in energy and metabolism. Currently, however, functionally relevant targets of Trx1 during myocardial ischemia are unknown.
During myocardial ischemia, the low-energy sensor, 5 0 -AMPactivated protein kinase (AMPK), is activated and stimulates adaptive mechanisms to restore the cellular energy conditions (Russell et al., 2004) . AMPK activity is tightly regulated at Thr172 in its activation segment by phosphorylation by AMPK kinases (AMPKKs) or allosteric prevention of dephosphorylation when high levels of AMP or ADP bind to the g subunit (Hawley et al., 1996; Oakhill et al., 2011) . Due to its master role in controlling both cellular and whole-body metabolic responses, AMPK is becoming a promising therapeutic target for insulin resistance, type 2 diabetes, metabolic syndrome, and obesity, all energy balance disorders (Hardie, 2008) . Complications of these metabolic disorders, which occur more frequently with aging, are associated with chronic ROS accumulation and correlate with insensitivity of AMPK activation to various stimuli (Reznick et al., 2007; Sciarretta et al., 2012; Sriwijitkamol et al., 2007) . However, whether direct posttranslational oxidative modification affects AMPK activity during metabolic stress is currently unknown.
Using mice harboring a Trx1 substrate-trapping mutant, we identified AMPKa as a target of Trx1 that is critical to cardiac protection against ischemia. During myocardial ischemia, oxidation of Cys130 and Cys174 causes aggregation of AMPK through intermolecular disulfide bond formation, which prevents phosphorylation/activation of AMPK by upstream AMPKKs. However, endogenous Trx1 prevents this oxidation in response to oxidative stimulus. High-fat diet (HFD) consumption decreased Trx1 expression and increased AMPK oxidation, enhancing susceptibility to myocardial infarction. Thus, AMPK activation is critically regulated by intracellular redox status, and Trx1 acts as an essential cofactor, allowing AMPK activation to occur during energy stress by preventing oxidative aggregation.
RESULTS

AMPK Is a Direct Target of Trx1
Mutation of Cys35 in the catalytic center to serine (C35S) allows Trx1 to trap its substrates by preventing completion of the thioldisulfide exchange reaction ( Figure 1A ) (Verdoucq et al., 1999) . In order to identify cardiac Trx1 targets in vivo, we generated transgenic mice with cardiac-specific expression of epitope (N-terminal FLAG and C-terminal HA)-tagged Trx1C35S (TgTrx1C35S). Three lines of transgenic mice were generated, and the one with the lowest transgene expression (line 1, Figure S1A , available online) was used in further experiments. All three lines exhibited apparently normal baseline cardiac phenotypes, (B) Tg-Trx1, Tg-Trx1C35S, Tg-Trx1C32S/C35S, and control WT mice were subjected to ischemia for 3 hr. The myocardial infarct area/area at risk (% infarct size/ AAR) is shown (*p < 0.05 versus WT; #p < 0.05 versus Tg-Trx1; n = 4-6). (C) Tg-Trx1C35S and WT mice were subjected to ischemia for 20 min. Homogenates prepared from sham-operated hearts and ischemic areas were used for coimmunoprecipitation, and immunoblots for the indicated molecules were performed. Error bars represent SEM.
including heart weight/body weight, an index of cardiac hypertrophy ( Figure S1B ). To examine the role of Trx1 during energy starvation in vivo, mice were subjected to myocardial ischemia, and the extent of myocardial infarction was evaluated. Transgenic mice with cardiac-specific overexpression of Trx1 (TgTrx1) exhibited significantly less myocardial infarction, whereas Tg-Trx1C35S mice and transgenic mice with cardiac-specific overexpression of a dominant negative Trx1 mutant (C32S/ C35S) (Tg-Trx1C32S/C35S) had significantly more infarction than wild-type (WT) mice after 3 hr of ischemia ( Figure 1B) . The percentage of Hairpin-2 positive nuclei, indicating necrotic cell death, was significantly lower in Tg-Trx1, but higher in TgTrx1C35S and Tg-Trx1C32S/C35S, than in WT mice after ischemia ( Figure S1C ). These data suggest that the Trx1 thioldisulfide exchange reaction protects the heart against prolonged ischemia.
To identify the Trx1 substrates involved in this cardioprotection, heart homogenates were prepared from WT and TgTrx1C35S mice, and proteins that form a disulfide bond with Cys32 of Trx1C35S were coprecipitated with a FLAG antibody and analyzed by immunoblot. N-Ethylmaleimide (NEM) (20 mM) was added to the lysis buffer to block free thiol groups and prevent spontaneous cysteine oxidation during protein sample extraction, which can lead to nonspecific capture by the Trx1-trapping mutant. Peroxiredoxin, a well-known Trx1 target, was one of the proteins identified through this analysis ( Figure S1D ), confirming the efficacy of the trapping mutant in vivo. Of the proteins identified (Figures 1C and S1D; Table  S1 ), we focused on the AMPK a subunit because of its importance in protecting the heart against ischemic injury (Russell et al., 2004) and the absence of prior evidence that thiol-disulfide exchange is involved in its regulation.
Endogenous AMPKa and Trx1 were present in both cytosol and nucleus in cardiomyocytes (Figures 2A and 2B) , and they interacted with one another in both cardiomyocytes in vitro and the heart in vivo ( Figure 2C ). To determine whether AMPKa forms a disulfide bond with Trx1, their interaction was examined after mutation of the Trx1 active site. H 2 O 2 enhanced interaction of AMPKa with Trx1C35S, but not with WT Trx1 or Trx1C32S/ C35S ( Figure 2D ). The interaction between Trx1C35S and AMPKa was almost completely abolished by addition of dithiothreitol (DTT), a reducing agent that cleaves disulfide bonds (Figure 2E) . These results suggest that AMPKa and Trx1 interact at baseline and that oxidative stress further stimulates disulfide bond formation between AMPKa and Cys32 in Trx1C35S. The expected increase in intermolecular disulfide bond formation between AMPKa and WT Trx1 in response to H 2 O 2 was not apparent due to completion of the thiol-disulfide exchange reaction via the reduced Cys35 in WT Trx1. Overexpression of WT Trx1, but not C35S or C32S/C35S mutants, prevented AMPK inactivation in response to H 2 O 2 ( Figure S2A ), indicating that the enzymatic activity of Trx1 is required to maintain AMPK activity in the presence of oxidative stress.
Phosphorylation of AMPKa and its substrate acetyl-CoA carboxylase (ACC) was increased in the ischemic heart. However, the increase in phosphorylation was abolished in TgTrx1C35S and Tg-Trx1C32S/C35S mice ( Figures 2F and S2B) , suggesting that the oxidoreductase activity of Trx1 is required for ischemia-induced AMPK activation in vivo.
Trx1 Acts as a Cofactor of AMPK in Response to Energy Stress An adenovirus harboring Trx1 shRNA (Ad-sh-Trx1) significantly inhibited glucose-deprivation (GD)-induced phosphorylation of both AMPKa and ACC in cardiomyocytes ( Figure 3A) , indicating that endogenous Trx1 plays an essential role in mediating AMPK activation in vitro.
AMPK activation during energy stress induces translocation of glucose transporter 4 (Glut4), which in turn stimulates glycolysis in cardiomyocytes (Russell et al., 2004) . Immunostaining and immunoblot analyses of the membrane fraction showed that Trx1 downregulation disrupted GD-induced Glut4 translocation to the plasma membrane ( Figures 3B and S3A ). GDinduced phosphorylation of phosphofructokinase 2 (PFK-2) and increases in the glycolysis rate were also attenuated in Ad-sh-Trx1-treated cardiomyocytes ( Figure 3C ). GD-induced decreases in ATP content and cell survival were exacerbated in cardiomyocytes treated with Ad-sh-Trx1 compared to in those with Ad-sh-scramble ( Figures 3D and S3B ). This effect was similar to that observed with dominant negative AMPK adenovirus (Ad-dn-AMPK) ( Figures 3D and S3B ). Suppression of AMPK in the presence of Trx1 downregulation did not further increase GD-induced cell death ( Figure 3D ). On the other hand, overexpression of either AMPK or Trx1 prevented GD-induced cell death ( Figures S3C and S3D ). Together, these data suggest that Trx1 plays an essential role in mediating AMPK activation and adaptive responses during GD.
Interestingly, both GD and 5-amino-1-b-Dffff-ribofuranosylimidazole-4-carboxamide (AICAR), which activates AMPK, also upregulated Trx1, an effect that was abolished in the presence of Ad-dn-AMPK ( Figures S3E and S3F) . Thus, AMPK activation is necessary and sufficient for Trx1 upregulation, suggesting that AMPK and Trx1 coordinately regulate each other during energy stress.
Trx1 Prevents Oxidation of AMPK in Response to Energy Stress
Since the oxidoreductive activity of Trx1 is required for AMPK activation during energy stress, we hypothesized that AMPKa undergoes oxidative modification. GD significantly induced H 2 O 2 production, as evaluated with CM-H 2 DCFDA staining (Figure S4A) . In order to examine whether AMPKa exhibits an electrophoretic mobility shift indicative of oxidative modification in response to energy stress, cardiomyocytes were incubated with glucose-free medium. Cardiomyocytes were also treated with H 2 O 2 as an exogenous oxidant to examine oxidation of AMPK. Cell lysates were separated by SDS-PAGE under nonreducing conditions in the absence of b-mercaptoethanol (BME). Duplicate samples were run on 6% and 8% gels in order to separate both high-and low-molecular-weight proteins reactive with the AMPKa antibody ( Figure S4B ). Immunoblot analyses revealed that AMPKa shifted to high molecular weights, and monomeric AMPKa was decreased in GD-or H 2 O 2 -treated myocytes (Figures 4A and 4B) . BME abolished these mobility shifts, suggesting that the slow-migrating AMPKa immunoreactive complex most likely represents oxidative aggregation caused by disulfide bond formation (Figures 4A and 4B) . Trx1 downregulation significantly weakened the monomer and increased the shift of AMPKa to higher molecular weights during GD or H 2 O 2 treatment (Figures 4A and 4B) , suggesting that endogenous Trx1 is essential in preventing AMPKa oxidation. Increased oxidative aggregation and decreased monomeric AMPKa were also observed in ischemic hearts ( Figure S4C ), suggesting AMPKa disulfide bond formation in vivo. Electrophoresis of recombinant AMPKa2, the predominant a subunit in the heart, also revealed a mobility shift that was dose-dependently exacerbated by H 2 O 2 ( Figure 4C ), indicating that cysteine oxidation in the a subunit is sufficient for aggregate formation. Consistent with the biochemical data, immunofluorescent staining with AMPKa antibody revealed a punctate pattern indicative of AMPKa aggregation after H 2 O 2 treatment ( Figure 4D ). Together, these results suggest that Trx1 inhibits disulfide bond formation in AMPKa during energy stress. To evaluate the redox status of cysteines in AMPKa, pulldown assays were performed with biotinylated iodoacetamide (IAM). IAM covalently binds to cysteine thiol groups only when they are in the reduced form. With increasing concentrations of H 2 O 2 , the amount of IAM-labeled AMPKa decreased significantly ( Figure 4E ). However, overexpression of Trx1 maintained the amount of reduced form AMPKa even in the presence of H 2 O 2 (10 mM) ( Figure S4D ). These data indicate that AMPKa contains redox-sensitive cysteines that are rapidly oxidized during oxidative stress and can be reduced by Trx1. Although H 2 O 2 did not significantly affect basal AMPKa Thr172 phosphorylation, it dose-dependently suppressed AICAR-induced phosphorylation and activation of AMPK ( Figures S4E-S4H ). Thus, cysteine oxidation blocks AICARinduced AMPK activation, mimicking the effect of Trx1 downregulation during energy starvation. High-dosage (300 mM) H 2 O 2 inhibited AMPK activity in cardiomyocytes even at baseline ( Figure S4I ) and caused strong oxidative aggregation of AMPK ( Figure S4J ). In contrast, the same dose of H 2 O 2 induced AMPK activation in HEK293 cells ( Figure S4I ), consistent with previous findings (Zmijewski et al., 2010) . There was no AMPK aggregation or decrease in monomeric AMPK in the presence of H 2 O 2 in HEK293 cells ( Figure S4J ), suggesting that oxidative aggregation and the amount of monomeric/ reduced AMPK critically regulate AMPK activity in both cell types.
To test whether AMPKa oxidation is reversible, cardiomyocytes were sequentially treated with H 2 O 2 and normal medium. After removal of H 2 O 2 , reduced-form AMPKa reappeared and reverted to normal levels ( Figure 4F ). To evaluate the relative importance of Trx1 and GSH, which also mediates protein disulfide reduction, in reduction of oxidized AMPK, we preincubated cardiomyocytes with either buthioninesulfoximine (BSO), an inhibitor of GSH synthesis, or 2,4-dinitro-1-chlorobenzene (DNCB), which prevents Trx recycling by inhibiting TrxR (Arné r et al., 1995). BSO decreased the GSH level by about 60%, whereas DMSO and DNCB did not ( Figure S4K ). DNCB completely prevented reduction and further enhanced oxidation of AMPKa upon removal of H 2 O 2 , whereas DMSO (vehicle) and BSO had no effect ( Figure 4F ). Thus, AMPKa oxidation is reversible and Trx1, but not GSH, is required to reduce the oxidized AMPKa in cardiomyocytes. 
Conserved AMPKa Cysteines Are Oxidized
Next, we investigated which AMPKa cysteine is sensitive to oxidation. Amino acid sequence alignment showed that Cys130 and Cys174 are the only two cysteines that are completely conserved from yeast to mammals ( Figure 5A ). To identify redox-sensitive cysteines, recombinant AMPKa2 was treated with or without 10 mM H 2 O 2 for 10 min. Reduced cysteines were then irreversibly labeled with IAM, whereas oxidized cysteines were first reduced with DTT and then labeled with S-Methyl methanethiosulfonate (MMTS). Tandem mass spectrometry (MS/MS) showed that a peptide containing Cys174 of AMPKa2 existed predominantly in an IAM-labeled (reduced) form in the control group but that an MMTS-labeled (oxidized) form appeared in the H 2 O 2 -treated group ( Figure 5B), suggesting that Cys174 is oxidized in response to H 2 O 2 . Cys130 and Cys490 were also oxidized in response to H 2 O 2 ( Figures S5A and S5B ).
At high doses of H 2 O 2 , Cys297, Cys382, and Cys543 were also found to be oxidized (data not shown), suggesting that more cysteines within the AMPKa2 subunit may be oxidized in the presence of severe oxidative stress.
We examined whether Cys130 or Cys174 is involved in the interaction with the catalytic motif of Trx1. As expected, the interaction between WT AMPKa2 and Trx1C35S was enhanced in the presence of H 2 O 2 ( Figure 5C ). A single mutation to serine at Cys130 (AMPKC130S) or Cys174 (AMPKC174S) did not abolish the H 2 O 2 -induced increase in interaction between AMPKa2 and Trx1C35S ( Figure 5C , left panel). However, mutation of both Cys130 and Cys174 to serine (AMPK2CS) did inhibit the H 2 O 2 -induced increase in interaction with Trx1C35S ( Figure 5C , right panel). Addition of a third mutation to serine at Cys490 (AMPK3CS) did not further decrease interaction with Trx1C35S, suggesting that Cys130 and Cys174 are the two major cysteines AMPK2CS had markedly reduced IAM labeling at baseline and in response to H 2 O 2 , suggesting that Cys130 and Cys174 are the major cysteines that undergo oxidation ( Figure S5C , left panel). Trx1 downregulation significantly reduced IAM labeling of AMPK in Ad-AMPKWT-transduced cardiomyocytes at baseline and further in response to GD ( Figure S5C, right panel) , suggesting that endogenous Trx1 reduces Cys130/174. To investigate whether AMPK molecules form intermolecular disulfide bonds with each other, FLAG/HA-and myc-tagged AMPK were coexpressed in Cos7 cells and coimmunoprecipitated. FLAG-AMPKC130S-HA, in which only Cys174 is redox sensitive, was used to evaluate disulfide formation at Cys174. H 2 O 2 enhanced the interaction of FLAG-AMPKC130S-HA with myc-AMPK WT, myc-AMPKC130S, and myc-AMPKC174S, but not myc-AMPK2CS, and DTT abolished the effect ( Figure S5D ). Thus, Cys174 in one molecule forms an intermolecular disulfide bond with Cys130 or Cys174 in another molecule ( Figure S5E ). The H 2 O 2 -induced mobility shift and decreases in monomeric AMPK were partially attenuated in AMPKC130S-and AMPKC174S-transduced myocytes compared to in AMPKWTtransduced myocytes and were completely abolished in AMPK2CS-transduced myocytes ( Figure 5D ), suggesting that the electrophoretic mobility shift of AMPK is mediated by oxidation of Cys130 and Cys174.
To determine whether Cys130 and Cys174 in AMPK are oxidized in response to GD in situ, FLAG-AMPK-HA immunoprecipitated from cardiomyocytes was analyzed by quantitative mass spectrometry (MS). MMTS labeling at Cys130 and Cys174, reflecting the oxidized form, was slightly increased in the GD-treated group and significantly enhanced in the same group when endogenous Trx1 was knocked down ( Figure 5E ). These data suggest that Cys130 and Cys174 are oxidized in response to GD but that endogenous Trx1 effectively attenuates this oxidation in cardiomyocytes.
Redox-Sensitive Cysteines Regulate AMPK Activity It has been proposed that dimerization of the kinase domain of yeast Snf1, a member of the Snf1/AMPK protein family, naturally inactivates it by burying the activation segment and substratebinding site (Nayak et al., 2006) . We speculated that oxidative aggregation physically interferes with access of AMPKKs to the activation domain of AMPK, thereby inhibiting its phosphorylation and activation. To test this hypothesis, AMPK phosphorylation assays were performed with a mixture of LKB1, an AMPKK, and its regulatory subunits, STRAD and MO25, collectively termed the LKB1 complex, before and after oxidation. When phosphorylation preceded H 2 O 2 treatment, AMPKa was labeled with radioactive ATP, and phosphorylated AMPKa was observed at higher molecular weights after H 2 O 2 treatment ( Figure 6A , lanes five and six). However, when H 2 O 2 treatment preceded the kinase reaction, radioactive labeling of AMPKa was markedly attenuated ( Figure 6A, lanes seven and eight) , suggesting that oxidized AMPK cannot be phosphorylated by AMPKK.
To elucidate the functional significance of cysteine modification in AMPK, the activities of AMPKC130S and AMPKC174S were examined. AMPKWT phosphorylation and kinase activity were enhanced by GD ( Figure 6B ). However, neither AMPKC130S nor AMPKC174S was phosphorylated at Thr172 or activated in response to GD ( Figure 6B ). The AMPK protein levels were similar for AMPKWT, AMPKC130S, and AMPKC174S, and the b2 and g1 subunits bound to the mutants to a similar degree as to AMPKWT ( Figure 6B ), indicating that the mutations did not affect AMPK stability or heterotrimer complex formation. Immunofluorescent staining showed that AMPKWT, AMPKC130S, and AMPKC174S were all present in both cytosol and nucleus ( Figure S6A ), indicating that the mutations did not affect the subcellular distribution of AMPK.
To further clarify the role of Cys130 and Cys174 in mediating AMPK activation, we generated ten different AMPKa2 mutants, in each of which a cysteine residue was replaced with a serine. Of these, only AMPKC130S and AMPKC174S failed to exhibit kinase activity in response to energy starvation in intact cells (Table S2) . Although AMPKC106S exhibited a 20% reduction in kinase activity compared to WT, Cys106 oxidation was never observed, either in the MS experiments or as a change in the mobility shift pattern. The other seven mutants showed normal Thr172 phosphorylation and kinase activity. These data indicate that Cys130 and Cys174 are responsible for AMPK oxidation and are critical in the regulation of AMPK activation.
In in vitro kinase assays, LKB1 phosphorylated GST-AMPKWT and increased its kinase activity 6-fold. However, AMPKC130S and AMPKC174S were not phosphorylated by LKB1, and their kinase activities remained at baseline levels even in the presence of LKB1 (Figures 6C and 6D) . AMPK mutants in which Cys130 or Cys174 was substituted with alanine (AMPKC130A or AMPKC174A) were not phosphorylated or activated in vitro or in vivo ( Figures S6B and S6C) , suggesting that structural modification of Cys130 or Cys174 inhibits AMPK activation. Similarly, AMPK, which had been alkylated with either IAM or NEM to block free thiol groups, was neither phosphorylated nor activated in the presence of LKB1 ( Figures S6D and S6E ). Since oxidative aggregation also prevents phosphorylation of AMPK by LKB1 ( Figure 6A ), these results suggest that the structural integrity of Cys130 and Cys174 is required for AMPK phosphorylation and (D) Cardiomyocytes transduced with the indicated adenoviruses harboring C-terminal HA-tagged AMPK were incubated with or without H 2 O 2 for 30 min. The effect of mutation of AMPK on its oxidation was examined. (E) Cardiomyocytes transduced with N-terminal FLAG-and C-terminal HA-tagged AMPK (FLAG-AMPK-HA) adenovirus were incubated with glucose-free medium for 2 hr in the presence or absence of Ad-sh-Trx1. Lysates were prepared in the presence of 100 mM IAM to label reduced cysteines. Oxidized cysteines were reduced with TCEP followed by MMTS alkylation. Samples were then immunoprecipitated with anti-FLAG agarose beads, and immunoprecipitates were analyzed by MS. The overlay extracted ion chromatograms of peptides LFQQILSAVDYC MMTS HR (A), corresponding to oxidized C130, and TSC MMTS GSPNYAAPEVISGR (B), corresponding to oxidized C174, in control (blue line), GD (green line), and GD plus Ad-sh-Trx1 (red line) samples are shown. Ratios of the oxidized peptide peak heights relative to those of the control groups are also shown (*p < 0.05 versus control; #p < 0.05 versus GD; n = 5). Error bars represent SEM.
activation. Coimmunoprecipitation experiments revealed that the physical interaction of LKB1 with AMPKWT, but not with AMPKC130S or AMPKC174S, was enhanced in response to GD ( Figure 6E ), suggesting that the presence of cysteines at 130 and 174 is required for assembly of the LKB1/AMPK enzyme-substrate complex and the subsequent phosphorylation/activation process during energy stress. Thus, alteration of the structure of Cys130 or Cys174 through disulfide bondmediated oxidation, amino acid substitution, or chemical alkylation blocks AMPK activation.
To further confirm that the cysteine modifications specifically affect LKB1 phosphorylation of AMPK, but not the intrinsic kinase activity of AMPK, we generated constitutively active AMPK (CA-AMPK), consisting of only the kinase domain of the a2 subunit, with or without cysteine-to-serine mutations at amino acids 130 and 174. Addition of the C130S, C174S, or 2CS muta- tion to CA-AMPK did not affect its kinase activity, as evidenced by phosphorylation of ACC ( Figure 6F ). Thus, it appears that the conserved cysteines are required for activation of WT AMPK through AMPKK-mediated phosphorylation and conformational change, but not for kinase activity in CA-AMPK, which does not require activation by AMPKK.
Functional Significance of Redox-Sensitive Cysteines in AMPKa
We examined the functional effect of the CS mutants in vitro. Endogenous AMPKa2 in cardiomyocytes was downregulated by transduction with AMPKa2 shRNA adenovirus (Ad-shAMPKa2) and then reconstituted with Ad-AMPK WT or CS mutants to the same level of AMPK expression as in control myocytes ( Figure S7A ). AMPKa2 downregulation enhanced GD-induced cardiomyocyte death. Restoration with the WT protein normalized GD-induced cell death to the same level as in the control group (Ad-sh-con) but reconstitution with AMPKC130S or AMPKC174S did not (Figure S7B) . In addition, overexpression of either AMPKC130S or AMPKC174S attenuated GD-induced phosphorylation of PFK-2 ( Figure S7C ).
We next evaluated the functional significance of the CS mutations in vivo. Since AMPKC130S and AMPKC174S behave the same with regard to both oxidation and kinase activity, we focused on C174S. To this end, we generated two lines of transgenic mice with high and low levels of cardiac-specific expression of AMPKC174S (Tg-AMPKC174S) ( Figure S7D ). Expression of AMPKC174S reduced the endogenous AMPKa2 protein level, probably by destabilizing it through competition for endogenous b and g subunit binding, and was accompanied by decreased Thr172 phosphorylation of AMPKa ( Figure S7D ). Tg-AMPKC174S (line 13) exhibited greater myocardial infarction than WT mice in response to ischemia ( Figure 7A ). Thus, intact Cys130 and Cys174 are required to promote cell survival during energy stress both in vitro and in vivo.
HFD Enhances AMPK Oxidation
Obesity and metabolic syndrome are associated with greater cardiovascular mortality and increased susceptibility to myocardial ischemia and heart failure (Abdulla et al., 2008) . We investigated whether AMPK is oxidized during metabolic stress using a mouse model of obesity (Sciarretta et al., 2012) . HFD consumption by C57BL/6J mice for 18-20 weeks induced AMPK inactivation in the heart, accompanied by decreased Trx1 expression, AMPK cysteine oxidation, and exacerbation of myocardial infarction following prolonged ischemia ( Figures 7B and 7D) . However, increased Trx1 expression in Tg-Trx1 prevented AMPK oxidation and maintained AMPK activity in the heart even after HFD treatment ( Figure 7C ). Tg-Trx1 were also protected against the HFD-induced exacerbation of myocardial infarction ( Figure 7D ), suggesting that restoration of Trx1 rescues HFD-induced myocardial injury by preventing AMPK oxidation.
DISCUSSION
We demonstrate in this study that AMPK is a critical target of Trx1 oxidoreductase activity during energy starvation. In response to energy stress, AMPK forms oxidative aggregates through intermolecular disulfide bonds at the conserved Cys130 and Cys174 residues, which inhibit phosphorylation of AMPK by AMPKK. Trx1 supports AMPK activation by reducing these key residues, acting as an essential cofactor during energy starvation ( Figure S7E ). However, AMPK is oxidized and cannot be activated in the presence of enhanced oxidative stress or when Trx1 activity is suppressed. Insufficient AMPK activity may contribute to the pathogenesis of metabolic disorders and enhance the risk of cardiovascular disease development, so therapeutic strategies that prevent AMPK inactivation under adverse conditions such as chronic oxidative stress and aging may prove more effective.
Identification of Trx1 Targets during Myocardial
Ischemia Using Trx1-Trapping Mutant Identifying Trx1 substrates has been difficult due to the highly transient nature of the thiol-disulfide exchange reaction, but substitution of Trx1 Cys35 with serine halts the reaction midway, trapping the substrate (Verdoucq et al., 1999) . Although the Trx1-trapping mutant offers a convenient way to study the Trx1 regulatory network in cells, it can also detect nonphysiological interacting partners, usually containing surface disulfide bonds, even if they are not redox regulated due to the very high reactivity of the nucleophilic Cys32 (Hisabori et al., 2005) . Thus, physiological interaction between Trx1 and its potential substrates needs to be carefully evaluated.
To our knowledge, this method has not been used to identify relevant targets of Trx1 under stress in vivo. Using transgenic mice expressing the Trx1-trapping mutant in the heart, we were able to pull down peroxiredoxin, a well-known Trx1 substrate, confirming the validity of this genetic mouse tool. We used the mouse line with the lowest transgene expression to avoid nonspecific binding. We confirmed the physical interaction between Trx1 and AMPKa using multiple methods and showed that Trx1-mediated reduction of AMPKa at Cys130 and Cys174 is essential for AMPK function in the presence of energy stress. Thus, we believe that AMPK is a physiological target of Trx1. The Trx1-trapping mice, together with proteomics, detailed protein-protein interaction studies, and functional analyses, should allow us to identify additional functionally relevant Trx1 targets during other types of cardiac stress in vivo.
Trx1 Is a Cofactor of the AMPK Complex Necessary for its Activation A dynamic thiol exchange reaction occurs between the Trx1 active site and AMPK cysteines in the presence of oxidative stress. However, Trx1 and AMPK interact with one another even under unstimulated conditions in cardiomyocytes. We speculate that this partially involves Trx1 domains other than the catalytic motif, since Trx1C32S/C35S still interacted with AMPK, allowing Trx1 to readily reduce AMPK when Cys130 and Cys174 are oxidized. Trx1 thus acts as an indispensable cofactor of AMPK, suppressing oxidation and supporting activation of AMPK during energy stress.
The amino acid sequences around AMPK Cys130 and Cys174 share some common features with those around cysteines in NF-kB and Ref1 known to interact with Trx1 (Qin et al., 2000) . For example, the arginine at the P +2 position of Cys130 may be important for strong hydrophobic interaction with Trx1, and the glycine and leucine in the P À4 positions of Cys130 and Cys174, respectively, may allow interaction with the aromatic ring of Trp31 in Trx1 (Qin et al., 2000) . Both positions may help stabilize the complex between Trx1 and its substrates. Further investigation of the protein structure should clarify how Trx1 catalyzes reduction of AMPK at Cys130 and Cys174.
AMPK Is a Redox-Sensitive Kinase
Although AMPK is primarily thought of as an energy-sensitive kinase, recent studies have indicated that its activity is also regulated by oxidative stress. Several lines of evidence suggest that ROS inhibit AMPK activity (Dolinsky et al., 2009; Saberi et al., 2008) , but no study has addressed whether the suppression is mediated by direct posttranslational modification. Interestingly, exogenous oxidant treatment stimulates AMPK by modulating either LKB1 activity or intracellular AMP/ATP levels in some transformed cell lines (Cao et al., 2008; Han et al., 2010) . We demonstrate here that ROS negatively regulate the activity of AMPK in cardiomyocytes during energy starvation through direct posttranslational modification. Why is AMPK regulated differently by ROS in different cell types? We speculate that both the antioxidant level and the nature of the oxidative stress affect the overall effect of ROS upon AMPK activity. For example, the same dosage of H 2 O 2 induces AMPK oxidation in cardiomyocytes but not in HEK293 cells ( Figure S4J ). Compared to primary cardiomyocytes, transformed cell lines may have elevated levels of antioxidants such as Trx1 that prevent AMPK oxidation and aggregation. AMPK activity may also be regulated by distinct mechanisms under energy-sufficient and energy-deficient conditions. In HEK293 cells, S-glutathiolation at Cys299 and Cys304 of AMPKa1 is essential for H 2 O 2 -induced AMPK activation through modulation of the autoinhibitory domain under energy-sufficient conditions (Zmijewski et al., 2010) . Whether Cys130 and Cys174 are modified under these conditions in HEK293 cells is unknown, but mutation of Cys299 and Cys304 in AMPKa1 did not affect AICAR-induced AMPK activation, consistent with our observation in cardiomyocytes that neither Cys297 nor Cys302 in AMPKa2 is oxidized or involved in energy starvation-induced AMPK activation. Thus, posttranslational oxidative modifications of AMPK are stimulus dependent.
Mutation of the redox-sensitive cysteines to serines, which in theory should mimic the reduced form, also inhibits AMPK activation, and modification of the cysteines with either chemical alkylation or via mutation abolished the interaction between AMPK and LKB1 and AMPK Thr172 phosphorylation. Thus, intact and reduced thiols at Cys130 and Cys174 are prerequisite for AMPK activation, and redox regulation at these cysteines is essential for the AMPK-mediated survival effect during energy stress. This mechanism also provides insight as to how H 2 O 2 can stimulate AMPK in transformed cell lines such as HEK293, in which a relatively high antioxidant capacity may keep Cys130 and Cys174 in the reduced form even in the presence of H 2 O 2 . Under such conditions, strong oxidative stress caused by exogenous H 2 O 2 may allow AMPK to be activated by oxidation of another cysteine residue through some other posttranslational modification, such as S-glutathiolation.
How Does Oxidation of AMPK Affect Its Structure and Kinase Activity? Crystal structure analyses show that the yeast Snf1 kinase domain dimer is formed predominantly by hydrophobic interactions between residues within the T loop activation segment and the loop-aG region of the kinase domain (Nayak et al., 2006) . The interaction at the T loop activation segment takes place around Thr210, corresponding to Thr172 in AMPK, and involves the flanking residues, including Cys212, which corresponds to Cys174 in AMPK. Although the authors predicted that van der Waals interactions play a role in mediating the dimerization, two mutations of the hydrophobic core of the dimer interface (I257E and F261E) were not sufficient to disrupt Snf1 homodimerization in vivo, suggesting that other mechanisms may be involved. Our results suggest that intermolecular disulfide bonds involving Cys174 may be responsible for the dimer formation in AMPK.
Snf1 dimerization buries the activation segment and substrate-binding site deep inside the dimer, representing a natural, inactive form of Snf1 (Nayak et al., 2006) . Our results show that oxidative modification and amino acid substitution at Cys174 or Cys130 abolishes interaction between AMPK and LKB1 and Thr172 phosphorylation by LKB1. Furthermore, LKB1 cannot phosphorylate recombinant AMPK when the kinase reaction follows oxidation of AMPK in vitro. We speculate that the oxidative aggregate of AMPK physically interferes with access of LKB1 to the AMPK activation domain. Given that Cys130 is located on the surface of mammalian AMPK and close to the activation domain, oxidation of Cys130 in mammalian AMPK may also induce burial of the activation segment.
Since disulfide bond formation is a reversible process, it allows for tight control of AMPK activity through the balance between oxidative stress and the intact Trx1 system ( Figure 4F ). Indeed, Trx1-dependent reduction of AMPK is essential for AMPK activation by physiological stimuli such as energy starvation. Disulfide bond formation during AMPK oxidation can also prevent severe cysteine oxidation, which would irreversibly inhibit its kinase activity. Thus, the intermolecular disulfide bond of AMPK may also be adaptive against severe oxidative stress.
Biological Significance of AMPK as a Redox Sensor
How do myocardial ischemia and GD stimulate ROS production in cardiomyocytes? We recently showed that GD activates Nox4, a major isoform of the NADPH oxidase family that is localized on intracellular membranes (Sciarretta et al., 2013) . Changes in the activity of the antioxidants and transporters controlling intracellular and mitochondrial Ca 2+ levels may also contribute to increased ROS levels. In addition, activation of AMPK stimulates energy production pathways, including glycolysis and fatty acid oxidation, thereby indirectly increasing mitochondrial workload and consequent electron leakage. Interestingly, AMPK plays an essential role in upregulation of Trx1 in cardiomyocytes, which in turn prevents AMPK oxidation. AMPK activation also stimulates antioxidant capacity during energy stress (data not shown), which could be an adaptive mechanism to prevent ROS-induced damage. Thus, AMPK and Trx1 stimulate one another's activity, thereby helping to maintain the homeostasis of both energy and redox status in cardiomyocytes. We propose that AMPK has three different statuses: oxidized (inactive), reduced (activatable), and reduced and phosphorylated (active) ( Figure S7E ). The relative proportions of each form are determined by the intracellular energy status, ROS level, and Trx1 activity. Under physiological conditions, AMPK mainly remains in its reduced form in a Trx1-dependent manner. However, AMPK is oxidized and cannot be activated in the presence of enhanced oxidative stress or when Trx1 activity is suppressed. In our obese mouse model, we also observed decreased Trx1 protein expression.
The dual effect upon Trx1 activity and Trx1 expression may explain the enhanced AMPK oxidation and inactivation in these animals. Oxidative stress has been shown to promote Trx1 degradation in vascular cells (Zschauer et al., 2011) . Given that AMPK positively regulates Trx1, inhibition of AMPK may contribute to Trx1 suppression and ROS accumulation during the development of obesity or diabetes, which would further accelerate AMPK oxidation, leading to disruption of the redox and energy balances. AMPK plays a protective role in several human disorders, including myocardial ischemia, diabetes, obesity, and cancers. Knowledge obtained from this investigation should be useful for the development of therapeutic strategies by which AMPK may be activated even under adverse conditions such as oxidative stress and aging.
EXPERIMENTAL PROCEDURES Transgenic Mice
Transgenic mice expressing either hTrx1C32S/C35S (Tg-Trx1C32S/C35S) or WT hTrx1 (Tg-Trx1) were generated on an FVB background as described previously (Yamamoto et al., 2003) . Transgenic mice expressing either hTrx1C35S (Tg-Trx1C35S) or AMPKC174S (Tg-AMPKC174S) were generated on an FVB background using the a-myosin heavy chain promoter (courtesy of J. Robbins, University of Cincinnati, Cincinnati) to achieve cardiac-specific expression. Tg-Trx1 mice generated on a C57BL/6 background were used in the HFD study. All protocols concerning animal use were approved by the Institutional Animal Care and Use Committee at the New Jersey Medical School, Rutgers Biomedical and Health Sciences.
Immunoblot Analysis
Heart homogenates or cell lysates were prepared using RIPA buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholic acid, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 0.5 mg/ml aprotinin, and 0.5 mg/ml leupeptin. Equal amounts of proteins (10-20 mg) were subjected to SDS-PAGE. Nuclear and cytosolic fractions were prepared with NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce). After proteins were transferred to a PVDF membrane, immunoblots were probed with the indicated antibodies. Protein abundance was analyzed densitometrically and standardized with a-tubulin or GAPDH. For AMPK redox analysis, cardiomyocytes were incubated with ice-cold PBS containing 20 mM NEM for 15 min to block free thiol groups immediately after treatment and subsequently lysed with RIPA buffer containing 20 mM NEM to prevent further cysteine oxidation during protein extraction. Equal amounts of proteins were then subjected to SDS-PAGE with loading buffer with or without BME.
Immunoprecipitation
Heart homogenates or cell lysates were prepared using lysis buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, and 1 mM EDTA. The lysis buffer used to examine protein-protein interaction with Trx1 or its mutants was supplemented with 20 mM NEM to avoid spontaneous thiol oxidation during protein extraction or incubation. Lysates were incubated with 30 ml protein A agarose-immobilized antibody or 30 ml FLAG-agarose beads (Sigma) for 2 hr at 4 C. Immunocomplexes were washed with lysis buffer three times and eluted with 23 SDS sample buffer.
AMPK Kinase Assays
Immunocomplexes from Cos7 cells transfected with WT or mutant AMPK in the presence of normal or glucose-free medium were subjected to a standard AMPK kinase assay using SAMS as a substrate. A total of 1 mg of E. coli-expressed GST-AMPKa2 (WT or mutant) was maximally activated using MgATP and AMPKK, and 5 ml of the mixture was subjected to a standard AMPK kinase assay. The phosphorylation status of AMPK was detected by autoradiography.
Detection of Thiolate Cysteines
Cardiomyocytes plated on 6 cm dishes were treated with H 2 O 2 using the indicated times and doses and lysed with RIPA buffer containing 200 mM biotinylated-IAM (Sigma). The lysates were incubated with 25 ml streptavidin agarose beads (Sigma) for 2 hr at 4 C. After washing with lysis buffer three times, biotinylated proteins were eluted with 23 SDS sample buffer and subjected to immunoblot analysis.
Mass Spectrometry
Immunoprecipitated or E.coli-expressed proteins were separated by SDS-PAGE. The gel band corresponding to AMPKa2 was trypsin digested in gel without reduction/alkylation. The resulting peptides were subjected to liquid chromatography-MS/MS analysis on a U3000 LC coupled with an Orbitrap Velos tandem mass spectrometer (Thermo Fisher Scientific). MS/MS spectra were searched against a Swissprot rat database. Methionine oxidation, Cys methylthio (MMTS), and carbamidomethyl (IAM) modifications were set as variable modifications. The selected ion chromatogram peak areas of AMPKa2 peptides identified with either MMTS or IAM modifications were used for relative quantification after normalization with the average peak areas of two non-Cys-containing AMPKa2 peptides.
Statistical Analysis
All values are expressed as mean ±SEM. Statistical comparisons between groups were conducted by unpaired Student's t test or one-way ANOVA followed by a Newman-Keuls comparison test. The value of p < 0.05 was considered to be significant.
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